Triple negative breast cancer control through synergistic inhibition of EGFR and CDK9 signaling

Project Information

TRIPLECON

Grant agreement ID: 767854

DOI 10.3030/767854

Project closed

EC signature date 18 September 2017

Start date 1 October 2017

End date 30 September 2018

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 150 000,00

EU contribution € 150 000,00

Coordinated by

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands